<DOC>
	<DOC>NCT00860340</DOC>
	<brief_summary>To determine if the beneficial effect of spironolactone in patients with congestive heart failure is in part due to its intrinsic inotropic action. Randomized, two group placebo controlled, single blind study.</brief_summary>
	<brief_title>Hemodynamic Effects of Spironolactone in Patients With Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>CHF 21 80 years Serum creatinine &lt; 2 mg/dL Serum potassium 2.7 4.5 mg/dL measured within past 4 weeks Less than 21 years Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Hemodynamics</keyword>
	<keyword>Echocardiographs</keyword>
</DOC>